Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

Search for Alzheimer's drug unexpectedly finds possible biomarker (opens in a new tab)

medicalxpress.com · 2026-10-20

Short answerEvidenceSource

Short answer

Mostly not supported

Mostly not supported.

2 claims go further than the study. 2 other points were not covered by the paper.

  • 1 supported
  • 2 overstated
  • 2 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mostly not supported

Two of five claims overstate the study. One of five checks out. Two claims the study doesn't address.

  • 1 supported
  • 2 overstated
  • 2 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

5 claims in this story

Showing all 5 claimsChoose a verdict to focus the list.

Claim 1 of 5OverstatedResearchers developed a drug for Alzheimer's disease and then discovered that the molecule already exists in human blood and is found at lower levels in cognitively impaired people.View evidenceHide evidence

Why this verdict

The abstract-level profile supports that HAEE was detected as an endogenous component of human plasma and that levels were significantly lower in clinically diagnosed AD patients than cognitively unimpaired controls. But the headline wording that researchers “developed a drug” overstates the paper’s abstract, which frames exogenous HAEE as a possible drug/clinical-trial candidate, not an established developed drug. The phrase “cognitively impaired people” is also broader than the reported AD-vs-control comparison. The headline outruns the story’s more tentative body framing of a possible treatment/biomarker.

1

Study evidence

HAEE peptide is detectable in human blood plasma and is reported by the authors to represent a normal endogenous plasma component (no exogenous dosing).

“We discover that HAEE peptide represents a normal endogenous component of human blood plasma.”
2

Study evidence

Endogenous HAEE was detected in human plasma and reported to be significantly reduced in patients with a clinical diagnosis of Alzheimer's disease (n = 200) compared with cognitively unimpaired controls (n = 150).

“the HAEE level has been significantly reduced in patients with a clinical diagnosis of AD (n = 200) as compared with the control participants with no clinical diagnosis of cognitive impairment (n = 150).”
Claim 2 of 5OverstatedThe authors suggest HAEE deficiency may be a cause of Alzheimer's disease and that HAEE blood concentration may be a useful biomarker to help diagnose the disease.View evidenceHide evidence

Why this verdict

The biomarker portion is supported only as an inferential proposal: the authors say HAEE deficiency may be considered a potential blood-based biomarker for AD diagnosis. However, saying HAEE deficiency may be a cause of AD is stronger than the abstract-level evidence supports. The supplied profile describes an observational AD-vs-control association and explicitly notes that temporal or causal interpretations are not supported by the presented data.

1

Study evidence

Endogenous HAEE was detected in human plasma and reported to be significantly reduced in patients with a clinical diagnosis of Alzheimer's disease (n = 200) compared with cognitively unimpaired controls (n = 150).

“the HAEE level has been significantly reduced in patients with a clinical diagnosis of AD (n = 200) as compared with the control participants with no clinical diagnosis of cognitive impairment (n = 150).”
2

Study evidence

Endogenous HAEE is detectable in human blood plasma and its concentration was reported as significantly reduced in participants with a clinical diagnosis of Alzheimer’s disease compared with control participants (AD n = 200; control n = 150).

“Deficiency of endogenous HAEE may be considered as a potential blood-based biomarker in the diagnosis of AD, while exogenous synthetic HAEE may serve as a drug in AD-modifying therapy.”
Claim 3 of 5Not coveredThe tetrapeptide Ac-His-Ala-Glu-Glu-NH2 (HAEE) blocks the primary zinc-binding center in amyloid-β monomers, and the authors reported promising results in mice.View evidenceHide evidence

Why this verdict

The abstract-level profile supports the broader idea that HAEE competitively inhibits Aβ–zinc interactions and suppresses Aβ aggregation in animal models. However, it does not verify the more specific wording that HAEE “blocks the primary zinc-binding center in amyloid-β monomers,” nor does it specify mice rather than animal models generally. Those details are not verifiable from the supplied abstract-depth profile.

1

Study evidence

HAEE peptide is detectable in human blood plasma and is reported by the authors to represent a normal endogenous plasma component (no exogenous dosing).

“We discover that HAEE peptide represents a normal endogenous component of human blood plasma.”
2

Study evidence

Endogenous HAEE is detectable in human blood plasma and its concentration was reported as significantly reduced in participants with a clinical diagnosis of Alzheimer’s disease compared with control participants (AD n = 200; control n = 150).

“Deficiency of endogenous HAEE may be considered as a potential blood-based biomarker in the diagnosis of AD, while exogenous synthetic HAEE may serve as a drug in AD-modifying therapy.”
Claim 4 of 5Not coveredAccording to the authors, HAEE levels correlate with disease status, while amyloid-β levels are the same in people with Alzheimer's disease and healthy people.View evidenceHide evidence

Why this verdict

The HAEE portion is broadly supported: plasma HAEE was reported as significantly reduced in clinically diagnosed AD patients versus controls. But the claim that amyloid-β levels are the same in people with AD and healthy people is not present in the supplied abstract-depth profile, which does not report amyloid-β level measurements or comparisons. At this evidence depth, that part is not verifiable.

1

Study evidence

Endogenous HAEE was detected in human plasma and reported to be significantly reduced in patients with a clinical diagnosis of Alzheimer's disease (n = 200) compared with cognitively unimpaired controls (n = 150).

“the HAEE level has been significantly reduced in patients with a clinical diagnosis of AD (n = 200) as compared with the control participants with no clinical diagnosis of cognitive impairment (n = 150).”
Claim 5 of 5SupportedSergey A. Kozin and colleagues designed a peptide to interfere with the growth of amyloid-β plaques in the brain by disrupting abnormal interactions between amyloid-β and zinc ions.View evidenceHide evidence

Why this verdict

The profile states that HAEE was engineered as a competitive inhibitor of amyloid-β–zinc interactions, with the Aβ 11–14 region and zinc binding described as relevant to aggregation/plaque biology. As framed as design/rationale rather than proven clinical efficacy, this is supported at abstract depth.

1

Study evidence

HAEE peptide is detectable in human blood plasma and is reported by the authors to represent a normal endogenous plasma component (no exogenous dosing).

“We discover that HAEE peptide represents a normal endogenous component of human blood plasma.”
2

Study evidence

Endogenous HAEE was detected in human plasma and reported to be significantly reduced in patients with a clinical diagnosis of Alzheimer's disease (n = 200) compared with cognitively unimpaired controls (n = 150).

“the HAEE level has been significantly reduced in patients with a clinical diagnosis of AD (n = 200) as compared with the control participants with no clinical diagnosis of cognitive impairment (n = 150).”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • The paper’s major methods contribution is development of an HPLC–MS(/MS) assay to monitor HAEE concentration in human blood plasma in preparation for clinical trials.

    The story presentation focuses on the unexpected endogenous finding, treatment possibility, and biomarker idea, but it does not reflect the analytical-method development as a primary contribution.

    From Analytical method development (HPLC–MS(/MS))

  • The biomarker interpretation is preliminary: the abstract provides no effect size, p-value, confidence interval, ROC/AUC, sensitivity/specificity, or independent validation to establish diagnostic utility.

    The story mentions biomarker usefulness but its listed caveats do not acknowledge that the abstract lacks quantitative diagnostic-performance information and validation needed to judge clinical utility.

    From case–control observational; interpretive synthesis / analytical assay development

  • The AD association is observational/case-control at abstract depth, with no reported temporal evidence or confounder adjustment; it does not support causal claims that HAEE deficiency causes AD.

    Although the story caveats say the causal interpretation is attributed to the authors rather than proven, the presentation still includes a causal-sounding deficiency-as-cause claim and does not acknowledge the key design limitation: cross-sectional observational evidence without reported confounder control.

    From case–control observational

2 things the story did carry across
  • The authors report that HAEE is detectable in human blood plasma and conclude it is a normal endogenous plasma component.
  • The paper reports an observational AD-vs-control comparison: plasma HAEE was significantly reduced in clinically diagnosed AD patients compared with cognitively unimpaired controls, with sample sizes n=200 AD and n=150 controls.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

4

Evidence read

study summary

Lead result

human in vivo

1Lead resulthuman in vivoTest whether endogenous HAEE levels differ between clinically diagnosed Alzheimer’s disease (AD) patients and cognitively unimpaired controls, proposing HAEE deficiency as a blood-based biomarker signal.case–control observationalExpand

In plain English

The authors developed an HPLC–MS assay for the synthetic peptide HAEE, discovered that HAEE is an endogenous component of human plasma, and report that plasma HAEE concentrations are significantly lower in clinically diagnosed Alzheimer's disease (AD) patients (n = 200) than in cognitively unimpaired control participants (n = 150); they propose HAEE deficiency as a potential blood-based biomarker for AD and note exogenous synthetic HAEE as a possible therapeutic.

Key findings

  • Endogenous HAEE was detected in human plasma and reported to be significantly reduced in patients with a clinical diagnosis of Alzheimer's disease (n = 200) compared with cognitively unimpaired controls (n = 150).
“the HAEE level has been significantly reduced in patients with a clinical diagnosis of AD (n = 200) as compared with the control participants with no clinical diagnosis of cognitive impairment (n = 150).”
What this piece can’t prove

2 further details could not be confirmed from the summary.

2ex vivo humanDevelop and describe an analytical HPLC–MS(/MS) method to monitor the synthetic peptide HAEE concentration in human blood plasma in preparation for clinical trials.Analytical method development (HPLC–MS(/MS))Expand

In plain English

Paper reports development of an analytical HPLC–MS(/MS) workflow to monitor the synthetic peptide HAEE in human blood plasma in preparation for clinical trials; the assay combines HPLC separation with mass detection of the parent quasi-molecular ion and fragment ions and was applied to human plasma where endogenous HAEE was detected and reported as reduced in patients clinically diagnosed with Alzheimer’s disease versus controls (n = 200 vs n = 150). Abstract-level text does not provide chromatographic conditions, MS transitions, sample-preparation details, or validation metrics.

Key findings

  • An analytical HPLC–MS(/MS) method to monitor HAEE in human blood plasma is described, combining HPLC separation and mass detection of parent and fragment ions.
  • Using the described assay, endogenous HAEE was detected in human plasma and reported to be significantly reduced in patients with a clinical diagnosis of Alzheimer's disease compared with control participants.Reported as significantly reduced (no numeric effect size provided in abstract)
“We sought to develop a reliable method for studying the behavior of the synthetic HAEE peptide in the human blood in preparation for clinical trials”
What this piece can’t prove
  • Abstract does not provide specific chromatography conditions (column type, mobile phases, gradient, run time).
  • No description of plasma sample preparation/extraction protocol (e.g., protein precipitation, solid-phase extraction).

3 further details could not be confirmed from the summary.

3ex vivo humanEstablish that HAEE is a normal endogenous component of human blood plasma (i.e., detectable in humans without exogenous dosing).Expand

In plain English

Using HPLC coupled with mass-spectrometric detection, the authors report that the engineered peptide Ac-His-Ala-Glu-Glu-NH2 (HAEE) is detectable in human blood plasma and conclude it represents a normal endogenous plasma component (no exogenous dosing).

Key findings

  • HAEE peptide is detectable in human blood plasma and is reported by the authors to represent a normal endogenous plasma component (no exogenous dosing).
“We discover that HAEE peptide represents a normal endogenous component of human blood plasma.”
What this piece can’t prove
  • Abstract does not describe sample provenance, handling, or controls that would support exclusion of exogenous contamination or intake as alternative sources for the peptide.

2 further details could not be confirmed from the summary.

4otherContextual therapeutic rationale: exogenous synthetic HAEE may serve as an anti-amyloid drug and endogenous deficiency may relate to AD pathophysiology.interpretive synthesis / analytical assay developmentExpand

In plain English

The authors interpret their empirical findings to propose two related clinical implications: (1) that an endogenous peptide with the sequence Ac-His-Ala-Glu-Glu-NH2 (HAEE) is present in human plasma and is significantly reduced in patients with clinically diagnosed Alzheimer’s disease (AD) versus control participants (AD n = 200; controls n = 150), supporting HAEE deficiency as a potential blood-based biomarker for AD; and (2) that exogenous synthetic HAEE—previously shown by the authors to act as a zinc-competitive inhibitor of Aβ–zinc interactions and to suppress Aβ aggregation in animal models—could serve as an AD-modifying therapeutic. These statements are framed in the abstract as inferential (‘may be considered’, ‘may serve’).

Key findings

  • Endogenous HAEE is detectable in human blood plasma and its concentration was reported as significantly reduced in participants with a clinical diagnosis of Alzheimer’s disease compared with control participants (AD n = 200; control n = 150).
  • Exogenous synthetic HAEE has been characterized by the authors as a zinc-competitive inhibitor of Aβ–zinc interactions and reportedly suppresses Aβ aggregation in animal models; the authors propose it may serve as an AD-modifying therapeutic.
“Deficiency of endogenous HAEE may be considered as a potential blood-based biomarker in the diagnosis of AD, while exogenous synthetic HAEE may serve as a drug in AD-modifying therapy.”
What this piece can’t prove
  • The abstract frames the biomarker and therapeutic implications as inferential ('may be considered', 'may serve'), indicating these are interpretive conclusions rather than completed clinical validations.

2 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Open the paper in Tessa

Beyond Alzheimer’s story: How an engineered molecule gained an endogenous essence

PNAS Nexus · 2026

Source record (opens in a new tab)

Why this one

Near certain

NewsLink found the paper. Tessa is where you inspect it deeply.

Papers considered

The selected paper, plus nearby candidates.

Crossref, PubMed, Europe PMC · 16 candidate papers

Candidate

ABNORMALITIES OF THE GLUCOSE TRANSPORTER AT THE BLOOD-BRAIN BARRIER AND IN THE BRAIN IN ALZHEIMER??S DISEASE

Alzheimer Disease & Associated Disorders · 1988 · Crossref

Source (opens in a new tab)

And 10 more candidates considered.